| Autor: |
Kato, Taigo, Fujita, Kazutoshi, Minami, Takafumi, Nagahara, Akira, Hyashi, Yujiro, Nakata, Wataru, Matsuzaki, Kyosuke, Nakano, Kosuke, Hatano, Koji, Kawashima, Atsunari, Imamura, Ryoichi, Takada, Shingo, Nishimura, Kensaku, Tsujihata, Masao, Takao, Tetsuya, Nakai, Yasutomo, Nakayama, Masashi, Nishimura, Kazuo, Uemura, Motohide, Uemura, Hirotsugu |
| Předmět: |
|
| Zdroj: |
International Journal of Clinical Oncology; Oct2022, Vol. 27 Issue 10, p1596-1604, 9p |
| Abstrakt: |
Background: In metastatic renal-cell carcinoma (mRCC), recent clinical trials have shown efficacy of first-line combination therapy, as evidenced by better clinical outcome over target therapy. However, there are insufficient real-world evidences in mRCC patients in Japan. Methods: We performed a multicenter retrospective study of 72 mRCC patients who received nivolumab plus ipilimumab as first-line treatment between September 2018 and July 2021. Patient's characteristics, clinical outcomes and safety were retrospectively reviewed. We analyzed overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) in patients treated with combination therapy. Results: Of all patients, the median age was 70 years (range, 36–86) and the major type of histology was clear cell RCC (n = 55; 76.4%). Progressive disease (n = 25; 34.8%) and irAEs (n = 22; 30.6%) were the most common causes for discontinuing treatment. Median PFS and OS seemed similar between patients who discontinued treatment because of irAEs and for patients who did not (p = 0.360 and p = 0.069, respectively). Importantly, for patients with synchronous metastatic disease at diagnosis (n = 56), nephrectomy before initiating nivolumab plus ipilimumab had a significantly positive impact on better OS when compared to that in patients without nephrectomy (p = 0.028). Conclusion: This study confirms efficacy and safety of nivolumab plus ipilimumab for mRCC patients in real-world settings. Furthermore, nivolumab plus ipilimumab was associated with a better outcome in patients who had undergone nephrectomy at diagnosis for synchronous mRCC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink